Design, synthesis, and pharmacological characterization of N - And O-substituted 5,6,7,8-tetrahydro-4H-isoxazolo[4,5-d]azepin-3-ol analogues: Novel 5-HT2A/5-HT2C receptor agonists with pro-cognitive properties

Journal of Medicinal Chemistry

Volumn 56, Issue 3, 2013, Pages 1211-1227

  Jensen, Anders A ^a   Plath, Niels ^b   Pedersen, Martin H F ^c   Isberg, Vignir ^a   Krall, Jacob ^a   Wellendorph, Petrine ^a,d   Stensbøl, Tine B ^b   Gloriam, David E ^a   Krogsgaard Larsen, Povl ^a   Frølund, Bente ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b H LUNDBECK A S   (Denmark)

^c TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 IODOBENZYL) 3 OXO 3,4,5,6,7,8 HEXAHYDRO 2H ISOXAZOLO[4,5 D]AZEPIN 6 IUM BROMIDE; 2 (3 IODOBENZYL) 3 OXO 3,4,5,6,7,8 HEXAHYDRO 2H ISOXAZOLO[4,5 D]AZEPIN 6 IUM BROMIDE; 2 (4 IODOBENZYL) 3 OXO 3,4,5,6,7,8 HEXAHYDRO 2H ISOXAZOLO[4,5 D]AZEPIN 6 IUM BROMIDE; 2 (6 CHLORO 5 FLUORO 1 INDOLYL) 1 METHYLETHYLAMINE; 2 BENZYL 3 OXO 3,4,5,6,7,8 HEXAHYDRO 2H ISOXAZOLO[4,5 D]AZEPIN 6 IUM FUMARATE; 2 ETHYL 3 OXO 2,3,4,5,6,7 HEXAHYDROISOXAZOLO[5,4, C]PYRIDIN 6 IUM FUMARATE; 2 ETHYL 3 OXO 3,4,5,6,7,8 HEXAHYDRO 2H ISOXAZOLO[4,5 D]AZEPIN 6 IUM FUMARATE; 2 METHYL 3 OXO 3,4,5,6,7,8 HEXAHYDRO 2H ISOXAZOLO[4,5 D]AZEPIN 6 IUM BROMIDE; 2 PROPYL 3 OXO 3,4,5,6,7,8 HEXAHYDRO 2H ISOXAZOLO[4,5 D]AZEPIN 6 IUM FUMARATE; 2,6 DIMETHYL 3 OXO 3,4,5,6,7,8 HEXAHYDRO 2H ISOXAZOLO[4,5 D]AZEPIN 6 IUM CHLORIDE; 3 BENZYLOXY 7,8 DIHYDRO 4H ISOXAZOLO[4,5 D]AZEPINE 6 IUM CHLORIDE; 3 ETHOXY 4,5,6,7 TETRAHYDROISOXAZOLO[5,4 C]PYRIDIN 6 IUM FUMARATE; 3 ETHOXY 7,8 DIHYDRO 4H ISOXAZOLO[4,5 D]AZEPINE 6 IUM CHLORIDE; 3 METHOXY 7,8 DIHYDRO 4H ISOXAZOLO[4,5 D]AZEPINE 6 IUM CHLORIDE; 5,6,7,8 TETRAHYDRO 4H ISOXAZOLO[4,5 D]AZEPIN 3 OL DERIVATIVE; 6 CHLORO 2 (1 PIPERAZINYL)PYRAZINE; 6 CHLORO 5 METHYL 1 [[2 [(2 METHYL 3 PYRIDYL)OXY] 5 PYRIDYL]CARBAMOYL]INDOLINE; 6 METHYL 3 METHOXY 7,8 DIHYDRO 4H ISOXAZOLO[4,5 D]AZEPINE 6 IUM CHLORIDE; 8,9 DICHLORO 2,3,4,4A TETRAHYDRO 1H PYRAZINO[1,2 A]QUINOXALIN 5(6H) ONE; ASENAPINE; CLOZAPINE; CP 809101; GLEMANSERIN; ISOXAZOLE DERIVATIVE; MIANSERIN; PNU 22394; SEROTONIN; SEROTONIN 2A AGONIST; SEROTONIN 2C AGONIST; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING ASSAY; CHEMICAL REACTION; COGNITION; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; MALE; MAZE TEST; MOLECULAR DOCKING; MOUSE; NONHUMAN; PSYCHOSIS; RAT; RECEPTOR AFFINITY; SPATIAL MEMORY; TASK PERFORMANCE;

AZEPINES; BIOLOGICAL AVAILABILITY; COGNITION; DRUG DESIGN; HEK293 CELLS; HUMANS; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTOR, SEROTONIN, 5-HT2C; SEROTONIN RECEPTOR AGONISTS;

EID: 84873919526     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm301656h     Document Type: Article

References (78)

1. Berger, M.; Gray, J. A.; Roth, B. L. The expanded biology of serotonin Annu. Rev. Med. 2009, 60, 355-366
2. Monti, J. M.; Jantos, H. The roles of dopamine and serotonin, and of their receptors, in regulating sleep and waking Prog. Brain Res. 2008, 172, 625-646
3. Gershon, M. D.; Tack, J. The serotonin signaling system: from basic understanding to drug development for functional GI disorders Gastroenterology 2007, 132, 397-414
4. Ramage, A. G.; Villalon, C. M. 5-Hydroxytryptamine and cardiovascular regulation Trends Pharmacol. Sci. 2008, 29, 472-481
5. Moltzen, E. K.; Bang-Andersen, B. Serotonin reuptake inhibitors: the corner stone in treatment of depression for half a century-a medicinal chemistry survey Curr. Top. Med. Chem. 2006, 6, 1801-1823
6. Gray, J. A.; Roth, B. L. The pipeline and future of drug development in schizophrenia Mol. Psychiatry 2007, 12, 904-922
7. Katzman, M. A. Current considerations in the treatment of generalized anxiety disorder CNS Drugs 2009, 23, 103-120
8. Goadsby, P. J. Serotonin receptor ligands: treatments of acute migraine and cluster headache Handb. Exp. Pharmacol. 2007, 129-143
9. Halford, J. C.; Harrold, J. A.; Boyland, E. J.; Lawton, C. L.; Blundell, J. E. Serotonergic drugs: effects on appetite expression and use for the treatment of obesity Drugs 2007, 67, 27-55
10. Kroeze, W. K.; Kristiansen, K.; Roth, B. L. Molecular biology of serotonin receptors structure and function at the molecular level Curr. Top. Med. Chem. 2002, 2, 507-528
11. Hannon, J.; Hoyer, D. Molecular biology of 5-HT receptors Behav. Brain Res. 2008, 195-213, 198
12. Millan, M. J.; Marin, P.; Bockaert, J.; la Cour, C. M. Signaling at G-protein-coupled serotonin receptors: recent advances and future research directions Trends Pharmacol. Sci. 2008, 29, 454-464
13. 3 receptors Trends Pharmacol. Sci. 2008, 29, 437-444
14. 2C): where structure meets function Pharmacol. Ther. 1998, 79, 231-257
15. 2 receptors CNS Neurol. Disord.: Drug Targets 2004, 3, 11-26
16. Gonzalez-Maeso, J.; Sealfon, S. C. Psychedelics and schizophrenia Trends Neurosci. 2009, 32, 225-232
17. 2A serotonin receptor biology: interacting proteins, kinases and paradoxical regulation Neuropharmacology 2011, 61, 348-354
18. 2B receptors Curr. Top. Med. Chem. 2010, 10, 493-503
19. Hutcheson, J. D.; Setola, V.; Roth, B. L.; Merryman, W. D. Serotonin receptors and heart valve disease-it was meant 2B Pharmacol. Ther. 2011, 132, 146-157
20. 2C receptor protein in the rat CNS Neuropharmacology 2000, 39, 123-132
21. 2C receptors in GABAergic cells of the anterior raphe nuclei J. Chem. Neuroanat. 2005, 29, 83-91
22. 2C receptor ligands Sci.World J. 2010, 10, 1870-1885
23. 2C receptor: preclinical and clinical progression in multiple diseases Curr. Opin. Drug Discovery Dev. 2008, 11, 438-445
24. 2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies Therapie 2005, 60, 441-460
25. 2C receptors as a potential therapeutic target for the design antiepileptic drugs Curr. Top. Med. Chem. 2005, 5, 59-67
26. 2C receptor agonists and the control of appetite Handb. Exp. Pharmacol. 2012, 349-356
27. A agonists and partial agonists: THIP (Gaboxadol) as a non-opioid analgesic and a novel type of hypnotic Biochem. Pharmacol. 2004, 68, 1573-1580
28. Krogsgaard-Larsen, P.; Hjeds, H. Organic hydroxylamine derivatives. X. Structural analogues of γ-aminobutyric acid (GABA) of the Isoxazole enol-betaine type. Synthesis of 5,6,7,8-tetrahydro-4 H -isoxazolo[4,5- d ]azepin-3-ol zwitterion and 4,5,6,7-tetrahydrisoxazolo[4,5- c ]pyridin-3-ol zwitterion Acta Chem. Scand. 1974, B28, 533-538
29. Krogsgaard-Larsen, P.; Hjeds, H.; Curtis, D. R.; Leah, J. D.; Peet, M. J. Glycine antagonists structurally related to muscimol, THIP, or isoguvacine J. Neurochem. 1982, 39, 1319-1324
30. Krogsgaard-Larsen, P.; Mikkelsen, H.; Jacobsen, P.; Falch, E.; Curtis, D. R.; Peet, M. J.; Leah, J. D. 4,5,6,7-Tetrahydroisothiazolo[5,4- c ]pyridin-3-ol and related analogues of THIP. Synthesis and biological activity J. Med. Chem. 1983, 26, 895-900
31. 1F agonists. WO/2011/123654 A1, 2011.
32. Krogsgaard-Larsen, P. Muscimol Analogues. II Synthesis of Some Bicyclic 3-Isoxazolol Zwitterions Acta Chem. Scand. 1977, B31, 584-588
33. Schlag, B. D.; Lou, Z.; Fennell, M.; Dunlop, J. Ligand dependency of 5-hydroxytryptamine 2C receptor internalization J. Pharmacol. Exp. Ther. 2004, 310, 865-870
34. 2C receptors Br. J. Pharmacol. 2002, 136, 510-519
35. 2C receptor agonist for the treatment of obesity J. Med. Chem. 2008, 51, 305-313
36. 2C agonist, shows activity in animal models of antipsychotic activity Neuropharmacology 2007, 52, 279-290
37. 2C receptors in CHO-K1 cells Br. J. Pharmacol. 1999, 128, 13-20
38. 2 receptor subtypes Eur. J. Pharmacol. 2001, 414, 23-30
39. 2A receptor inverse agonists as antipsychotics J. Pharmacol. Exp. Ther. 2001, 299, 268-276
40. Shahid, M.; Walker, G. B.; Zorn, S. H.; Wong, E. H. Asenapine: a novel psychopharmacologic agent with a unique human receptor signature J. Psychopharmacol. 2009, 23, 65-73
41. 2C receptors in the rabbit: high correlation with the profile for the human receptors Eur. J. Pharmacol. 2000, 406, 163-169
42. Lameh, J.; McFarland, K.; Ohlsson, J.; Ek, F.; Piu, F.; Burstein, E. S.; Tabatabaei, A.; Olsson, R.; Bradley, S. R.; Bonhaus, D. W. Discovery of potential antipsychotic agents possessing pro-cognitive properties Naunyn Schmiedeberg's Arch. Pharmacol. 2012, 385, 313-323
43. Thomsen, A. R. B.; Hvidtfeldt, M.; Bräuner-Osborne, H. Biased agonism of the calcium-sensing receptor Cell Calcium 2012, 51, 107-116
44. 2C receptors Naunyn Schmiedeberg's Arch. Pharmacol. 2004, 370, 114-123
45. Muntasir, H. A.; Takahashi, J.; Rashid, M.; Ahmed, M.; Komiyama, T.; Hossain, M.; Kawakami, J.; Nashimoto, M.; Nagatomo, T. Site-directed mutagenesis of the serotonin 5-hydroxytryptamine2c receptor: identification of amino acids responsible for sarpogrelate binding Biol. Pharm. Bull. 2006, 29, 1645-1650
46. 2 receptors J. Neurochem. 2005, 92, 375-387
47. 2A receptor with an agonist, a partial agonist and an antagonist: effects on apparent agonist affinities Biochem. Pharmacol. 1996, 51, 71-76
48. Rosenkilde, M. M.; Cahir, M.; Gether, U.; Hjorth, S. A.; Schwartz, T. W. Mutations along transmembrane segment II of the NK-1 receptor affect substance P competition with non-peptide antagonists but not substance P binding J. Biol. Chem. 1994, 269, 28160-28164
49. Hjorth, S. A.; Thirstrup, K.; Schwartz, T. W. Radioligand-dependent discrepancy in agonist affinities enhanced by mutations in the kappa-opioid receptor Mol. Pharmacol. 1996, 50, 977-984
50. Sagan, S.; Beaujouan, J. C.; Torrens, Y.; Saffroy, M.; Chassaing, G.; Glowinski, J.; Lavielle, S. High affinity binding of [3 H ]propionyl-[Met(O2)11] substance P(7-11), a tritiated septide-like peptide, in Chinese hamster ovary cells expressing human neurokinin-1 receptors and in rat submandibular glands Mol. Pharmacol. 1997, 52, 120-127
51. Rosenkilde, M. M.; Schwartz, T. W. Potency of ligands correlates with affinity measured against agonist and inverse agonists but not against neutral ligand in constitutively active chemokine receptor Mol. Pharmacol. 2000, 57, 602-609
52. 2A receptor model activated by steered molecular dynamics simulations J. Chem. Inf. Model. 2011, 51, 315-325
53. Ballosteros, J. A.; Weinstein, H. Integrated methods for the construction of three dimensional models and computational probing of structure function relations in G protein-coupled receptors. In Methods in Neurosciences; Sealfon, S. C.; Conn, P. M., Eds.; Academic Press: San Diego, CA, 1995; Vol. 25, pp 366-428.
54. Meltzer, H. Y.; Nash, J. F. Effects of antipsychotic drugs on serotonin receptors Pharmacol. Rev. 1991, 43, 587-604
55. Martin, G. E.; Elgin, R. J., Jr.; Mathiasen, J. R.; Davis, C. B.; Kesslick, J. M.; Baldy, W. J.; Shank, R. P.; DiStefano, D. L.; Fedde, C. L.; Scott, M. K. Activity of aromatic substituted phenylpiperazines lacking affinity for dopamine binding sites in a preclinical test of antipsychotic efficacy J. Med. Chem. 1989, 32, 1052-1056
56. Martin, G. E.; Elgin, R. J., Jr.; Kesslick, J. M.; Baldy, W. J.; Mathiasen, J. R.; Shank, R. P.; Scott, M. K. Block of conditioned avoidance responding in the rat by substituted phenylpiperazines Eur. J. Pharmacol. 1988, 156, 223-229
57. Meltzer, H. Y.; Massey, B. W.; Horiguchi, M. Serotonin receptors as targets for drugs useful to treat psychosis and cognitive impairment in schizophrenia Curr. Pharm. Biotechnol. 2012, 13, 1572-1586
58. 2C agonists as potential treatments for urinary incontinence Bioorg. Med. Chem. Lett. 2009, 19, 4999-5003
59. 2A agonists WIREs: Membr. Transp. Signaling 2012, 10.1002/wmts.42
60. 2A receptor affinities Chem Biodiversity 2009, 6, 692-704
61. Nichols, D. E. Hallucinogens Pharmacol. Ther. 2004, 101, 131-181
62. Sellin, A. K.; Shad, M.; Tamminga, C. Muscarinic agonists for the treatment of cognition in schizophrenia CNS Spectrosc. 2008, 13, 985-996
63. Dellu, F.; Mayo, W.; Cherkaoui, J.; Le Moal, M.; Simon, H. A two-trial memory task with automated recording: study in young and aged rats Brain Res. 1992, 588, 132-139
64. 2C receptors are involved in the ability of M100907 to suppress cortical glutamate release induced by NMDA receptor blockade J. Neurochem. 2009, 108, 521-532
65. Marquis, K. L.; Sabb, A. L.; Logue, S. F.; Brennan, J. A.; Piesla, M. J.; Comery, T. A.; Grauer, S. M.; Ashby, C. R., Jr.; Nguyen, H. Q.; Dawson, L. A.; Barrett, J. E.; Stack, G.; Meltzer, H. Y.; Harrison, B. L.; Rosenzweig-Lipson, S. WAY-163909 [(7b R,10a R)-1,2,3,4,8,9,10,10a-Octahydro-7b H -cyclopenta-[ b ][1,4]diazepino[6,7,1 hi ]indole]: a novel 5-hydroxytryptamine 2C receptor-selective agonist with preclinical antipsychotic-like activity J. Pharmacol. Exp. Ther. 2007, 320, 486-496
66. Landolt, H. P.; Wehrle, R. Antagonism of serotonergic 5-HT2A/2C receptors: mutual improvement of sleep, cognition and mood? Eur. J. Neurosci. 2009, 29, 1795-1809
67. Frydenvang, K.; Pickering, D. S.; Greenwood, J. R.; Krogsgaard-Larsen, N.; Brehm, L.; Nielsen, B.; Vogensen, S. B.; Hald, H.; Kastrup, J. S.; Krogsgaard-Larsen, P.; Clausen, R. P. Biostructural and Pharmacological Studies of Bicyclic Analogues of the 3-Isoxazolol Glutamate Receptor Agonist Ibotenic Acid J. Med. Chem. 2010, 53, 8354-8361
68. Høg, S.; Greenwood, J. R.; Madsen, K. B.; Larsson, O. M.; Frølund, B.; Schousboe, A.; Krogsgaard-Larsen, P.; Clausen, R. P. Structure-activity relationships of selective GABA uptake inhibitors Curr. Top. Med. Chem. 2006, 6, 1861-1882
69. Gottlieb, H. E.; Kotlyar, V.; Nudelman, A. NMR Chemical Shifts of Common Laboratory Solvents as Trace Impurities J. Org. Chem. 1997, 62, 7512-7515
70. Jensen, A. A.; Christesen, T.; Bølcho, U.; Greenwood, J. R.; Postorino, G.; Vogensen, S. B.; Johansen, T. N.; Egebjerg, J.; Bräuner-Osborne, H.; Clausen, R. P. Functional characterization of Tet-AMPA [tetrazolyl-2-amino-3-(3-hydroxy-5-methyl- 4-isoxazolyl)propionic acid] analogues at ionotropic glutamate receptors GluR1-GluR4. The molecular basis for the functional selectivity profile of 2-Bn-Tet-AMPA J. Med. Chem. 2007, 50, 4177-4185
71. 3 receptors: inhibition and potentiation of Cys-loop receptor signaling through a conserved transmembrane intersubunit site J. Biol. Chem. 2012, 287, 25241-25254
72. 6 receptor ligands Bioorg. Med. Chem. Lett. 2010, 20, 5431-5433
73. 3H]MK-801 binding to the N -methyl- d -aspartate receptor-ion channel complex by l -glutamate, glycine, and polyamines J. Neurochem. 1988, 51, 830-836
74. Paxinos, G.; Watson, C. The Rat Brain in Stereotaxic Coordinates. 4th ed.; Academic Press: San Diego, 1998.
75. Wellendorph, P.; Høg, S.; Sabbatini, P.; Pedersen, M. H.; Martiny, L.; Knudsen, G. M.; Frølund, B.; Clausen, R. P.; Bräuner-Osborne, H. Novel radioiodinated γ-hydroxybutyric acid analogues for radiolabeling and photolinking of high-affinity γ-hydroxybutyric acid binding sites J. Pharmacol. Exp. Ther. 2010, 335, 458-464
76. Dellu, F.; Fauchey, V.; Le Moal, M.; Simon, H. Extension of a new two-trial memory task in the rat: influence of environmental context on recognition processes Neurobiol. Learn. Mem. 1997, 67, 112-120
77. Dellu, F.; Mayo, W.; Vallee, M.; Le Moal, M.; Simon, H. Facilitation of cognitive performance in aged rats by past experience depends on the type of information processing involved: a combined cross-sectional and longitudinal study Neurobiol. Learn. Mem. 1997, 67, 121-128
78. Friesner, R. A.; Banks, J. L.; Murphy, R. B.; Halgren, T. A.; Klicic, J. J.; Mainz, D. T.; Repasky, M. P.; Knoll, E. H.; Shelley, M.; Perry, J. K.; Shaw, D. E.; Francis, P.; Shenkin, P. S. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy J. Med. Chem. 2004, 47, 1739-1749